Literature DB >> 1328694

Heparin, urokinase, and ancrod alter neutrophil function.

J A Freischlag1, M D Colburn, W J Quiñones-Baldrich, W S Moore.   

Abstract

Neutrophils (polymorphonuclear neutrophils [PMNs]) have been implicated as mediators of reperfusion injury. Heparin, urokinase, and ancrod are agents used routinely to prevent and treat thrombosis, yet their effects on PMN function are unknown. Therefore human PMNs were obtained and incubated for 30 minutes with either saline solution or one of the following pharmacologic agents, each tested at three different concentrations: group 1, saline solution (control, n = 14); groups 2 through 4, heparin (5000 units/ml, n = 8; 2500 units/ml, n = 6; and 1250 units/ml, n = 6, respectively); groups 5 through 7, urokinase (50,000 units/ml, n = 8; 25,000 units/ml, n = 6; and 12,500 units/ml, n = 6, respectively), and groups 8 through 10, ancrod (70 units/ml, n = 8; 35 units/ml, n = 6; and 17.5 units/ml, n = 6). Superoxide anion production was measured by the reduction of cytochrome c in a spectrophotometric assay. Chemotaxis was evaluated by the number of PMNs migrating across a filter with a Neuro Probe chamber (Neuro Probe, Cabin John, Md.). Phagocytosis was determined by the ingestion of opsonized zymosan particles by PMNs. Serum obtained from each PMN donor was used both to opsonize the zymosan and as a chemoattractant in the chemotaxis assay. Statistical comparison was evaluated by analysis of variance, and post hoc comparisons for each agent with control were performed with the unpaired Student t test. No agent, at any dose, significantly changed superoxide anion production compared with control cells. All three agents significantly inhibited PMN chemotaxis (p < 0.01). In the control group the number of PMNs counted was 27.6 +/- 4.9.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328694     DOI: 10.1067/mva.1992.39288

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis.

Authors:  Jiayue Ding; Da Zhou; Yanyu Hu; Omar Elmadhoun; Liqun Pan; Jingyuan Ya; Tingting Geng; Zhongao Wang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

2.  Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents.

Authors:  K Riesenberg; F Schlaeffer; A Katz; R Levy
Journal:  Br Heart J       Date:  1995-01

3.  Evaluation of neutrophil function during hemodialysis treatment in healthy dogs under anesthesia with sevoflurane.

Authors:  Shunsuke Shimamura; Ken Kimura; Masaaki Katayama; Tadahisa Mashita; Kenichi Maeda; Saori Kobayashi; Reeko Sato; Jun Yasuda
Journal:  J Vet Med Sci       Date:  2014-08-21       Impact factor: 1.267

4.  Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience.

Authors:  Jia-Yue Ding; Li-Qun Pan; Yan-Yu Hu; Gary B Rajah; Da Zhou; Chao-Bo Bai; Jing-Yuan Ya; Zhong-Ao Wang; Ke-Xin Jin; Jing-Wei Guan; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  CNS Neurosci Ther       Date:  2019-01-23       Impact factor: 5.243

5.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.